Key Points
- Major insider sales: Group Gp Lp Column III sold a combined 4,400,290 shares of Tenaya over Feb 10–11 (343,717 at $0.82 and 4,056,573 at $0.68), raising roughly $3.04 million and materially trimming its stake.
- Stock and analyst context: TNYA trades around $0.68 with a market cap of about $113.8M (50‑day/200‑day averages $0.81/$1.15) and carries a consensus "Moderate Buy" rating with an average target of $4.50 despite recent target cuts, while institutional ownership stands near 90.5%.
Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) major shareholder Group Gp Lp Column III sold 343,717 shares of the firm's stock in a transaction that occurred on Tuesday, February 10th. The shares were sold at an average price of $0.82, for a total transaction of $281,847.94. Following the completion of the transaction, the insider owned 4,253,298 shares in the company, valued at $3,487,704.36. The trade was a 7.48% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Large shareholders that own 10% or more of a company's stock are required to disclose their sales and purchases with the SEC.
Group Gp Lp Column III also recently made the following trade(s):
- On Wednesday, February 11th, Group Gp Lp Column III sold 4,056,573 shares of Tenaya Therapeutics stock. The stock was sold at an average price of $0.68, for a total value of $2,758,469.64.
Tenaya Therapeutics Stock Performance
Tenaya Therapeutics stock opened at $0.68 on Friday. The firm has a market capitalization of $113.83 million, a PE ratio of -0.88 and a beta of 3.18. Tenaya Therapeutics, Inc. has a one year low of $0.36 and a one year high of $2.35. The stock's 50 day moving average price is $0.81 and its 200 day moving average price is $1.15.
Tenaya Therapeutics (NASDAQ:TNYA - Get Free Report) last announced its earnings results on Monday, November 10th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.03. On average, analysts forecast that Tenaya Therapeutics, Inc. will post -1.35 earnings per share for the current fiscal year.
Analysts Set New Price Targets
TNYA has been the topic of a number of recent analyst reports. Morgan Stanley set a $2.00 target price on shares of Tenaya Therapeutics in a research note on Thursday, January 8th. Canaccord Genuity Group lowered their price objective on Tenaya Therapeutics from $6.00 to $5.00 and set a "buy" rating for the company in a report on Thursday, December 18th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Tenaya Therapeutics in a report on Wednesday, January 21st. HC Wainwright decreased their target price on Tenaya Therapeutics from $5.00 to $3.00 and set a "buy" rating for the company in a research report on Friday, December 12th. Finally, Chardan Capital dropped their price target on Tenaya Therapeutics from $9.00 to $8.00 and set a "buy" rating on the stock in a research report on Friday, December 12th. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Tenaya Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $4.50.
Check Out Our Latest Research Report on Tenaya Therapeutics
Hedge Funds Weigh In On Tenaya Therapeutics
Institutional investors have recently made changes to their positions in the stock. Comerica Bank acquired a new stake in shares of Tenaya Therapeutics during the 1st quarter worth approximately $50,000. AQR Capital Management LLC bought a new position in Tenaya Therapeutics during the 1st quarter worth $442,000. Woodline Partners LP grew its stake in Tenaya Therapeutics by 30,563.2% during the 1st quarter. Woodline Partners LP now owns 5,916,167 shares of the company's stock worth $3,373,000 after buying an additional 5,896,873 shares during the last quarter. CWM LLC increased its position in Tenaya Therapeutics by 25.2% in the second quarter. CWM LLC now owns 90,087 shares of the company's stock worth $55,000 after buying an additional 18,142 shares during the period. Finally, Savant Capital LLC bought a new stake in Tenaya Therapeutics in the second quarter valued at $52,000. 90.54% of the stock is owned by institutional investors.
About Tenaya Therapeutics
(
Get Free Report)
Tenaya Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of gene therapy solutions for cardiovascular diseases. Leveraging a proprietary adeno‐associated virus (AAV) platform, the company aims to deliver durable, one‐time treatments for patients suffering from genetic cardiomyopathies and other inherited heart disorders. Its research programs center on optimizing vector design, delivery methods and manufacturing processes to enhance tissue specificity and minimize immune responses.
Founded in 2018 and headquartered in San Carlos, California, Tenaya has built a diversified pipeline of product candidates targeting conditions such as hypertrophic cardiomyopathy and other genetically driven forms of heart disease.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
